statnews.com·Jun 11, 2026
Novartis is intensifying its focus on molecular glue therapies, while also addressing rising drug costs for seniors and showcasing promising early data from Enliven's leukemia drug. Additionally, SonoThera has secured $125 million to further its ultrasound-based gene delivery approach.
Novartis's decision to expand its molecular glue strategy is a significant development in drug discovery, potentially offering new therapeutic avenues and investment opportunities. This strategic move highlights an emerging trend in biotech where companies are focusing on innovative mechanisms to enhance drug efficacy, making it a key area to watch for advancements and potential partnerships in the healthtech and biotech sectors.